June 30, 2025
| Today’s news and insights for biopharma leaders
UPDATED
Expected readouts in obesity, lung cancer and atopic dermatitis headline a series of study results that could give the biotechnology sector a boost.
|
The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.
|
The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.
|
Study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of research overnight. Explore how a new class of drugs could mark the future of immunotherapy in
|
The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ post-treatment movement.
|
|
GSK transformed drug development by investing in claims data early and revealing critical treatment dynamics. Learn their approach to securing budget, maximizing ROI and de-risking programs in this webinar.
|
|
From Our Library
Webinar - on demand
Custom content for MMIT
|
Survey Report
Custom content for TriNetX
|
Playbook
Custom content for Inovalon
|
View all resources
What We’re Reading
Politico
|
| 
